Orla Cunningham
Overview
Explore the profile of Orla Cunningham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cunningham O, Brady D
Midwifery
. 2024 Nov;
127:103857.
PMID: 39492238
Background: Pregnancy yoga is a holistic practice to support the physiological and psychological changes women experience in pregnancy, with the potential to be offered by mainstream maternity services. Evidence suggests...
2.
Corbett G, Carmody D, Rochford M, Cunningham O, Lindow S, OConnell M
Eur J Obstet Gynecol Reprod Biol
. 2023 Jan;
282:24-30.
PMID: 36621262
Objective: The aim of this study was to present contemporary trends in opiate use disorder (OUD) and substance use in pregnancy in Ireland, with associated obstetric outcomes, over the last...
3.
Bone R, Fennell B, Tam A, Sheldon R, Nocka K, Varghese S, et al.
Antib Ther
. 2022 Oct;
5(4):258-267.
PMID: 36299415
Background: Interleukin (IL)25 has been implicated in tissue homeostasis at barrier surfaces and the initiation of type two inflammatory signaling in response to infection and cell injury across multiple organs....
4.
Brinth A, Svenson K, Mosyak L, Cunningham O, Hickling T, Lambert M
Sci Rep
. 2022 May;
12(1):8699.
PMID: 35610505
Administration of therapeutic antibodies can elicit adverse immune responses in patients through the generation of anti-drug antibodies that, in turn, reduce the efficacy of the therapeutic. Removal of foreign amino...
5.
Cunningham O, Scott M, Zhou Z, Finlay W
MAbs
. 2021 Nov;
13(1):1999195.
PMID: 34780320
Antibody-based drugs, which now represent the dominant biologic therapeutic modality, are used to modulate disparate signaling pathways across diverse disease indications. One fundamental premise that has driven this therapeutic antibody...
6.
Campbell S, DeBartolo J, Apgar J, Mosyak L, McManus V, Beyer S, et al.
MAbs
. 2021 Feb;
13(1):1883239.
PMID: 33557673
Despite substantial technological advances in antibody library and display platform development, the number of approved biotherapeutics from displayed libraries remains limited. , 20-50% of peripheral B cells undergo a process...
7.
Root A, Guntas G, Katragadda M, Apgar J, Narula J, Chang C, et al.
MAbs
. 2021 Jan;
13(1):1850395.
PMID: 33459147
We report here the discovery and optimization of a novel T cell retargeting anti-GUCY2C x anti-CD3ε bispecific antibody for the treatment of solid tumors. Using a combination of hybridoma, phage...
8.
Stack E, McMurray S, McMurray G, Wade J, Clark M, Young G, et al.
MAbs
. 2020 Apr;
12(1):1755000.
PMID: 32329655
The role of brain-derived neurotrophic factor (BDNF) signaling in chronic pain has been well documented. Given the important central role of BDNF in long term plasticity and memory, we sought...
9.
Fazavana J, Brophy T, Chion A, Cooke N, Terraube V, Cohen J, et al.
J Thromb Haemost
. 2020 Feb;
18(6):1278-1290.
PMID: 32108991
Background: Previous studies have demonstrated that the A1A2A3 domains of von Willebrand factor (VWF) play a key role in regulating macrophage-mediated clearance in vivo. In particular, the A1-domain has been...
10.
Arezes J, Foy N, McHugh K, Quinkert D, Benard S, Sawant A, et al.
Blood
. 2020 Jan;
135(8):547-557.
PMID: 31899794
Erythroferrone (ERFE) is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulation by BMP6. Hepcidin suppression allows for the mobilization of iron...